Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Organic radiopharmaceuticals: recent advances

Conference ·
OSTI ID:6165853
Organic radiopharmaceuticals are considered in light of accelerator and nuclide production requirements, special problems relating to the carrier-free state, including terminology, of the special technology required to prepare and manipulate these compounds and new trends in compound design and synthesis. The emphasis is on medical cyclotrons and the positron-emitting radionuclides, carbon-11, nitrogen-13, oxygen-15, and fluorine-18. New routes to synthetic precursors and organic compounds of high specific activity labeled with carbon-11, fluorine-18, and iodine-123 including monosaccharides, aromatic amines, neuroleptics, fatty acids, steroids, and other classes of compounds are discussed. Some compounds are considered in terms of the development and evaluation of structure-activity relationships and including some newer concepts such as metabolic trapping. 67 references.
Research Organization:
Brookhaven National Lab., Upton, NY (USA)
DOE Contract Number:
EY-76-C-02-0016
OSTI ID:
6165853
Report Number(s):
BNL-25850; CONF-790321-1
Country of Publication:
United States
Language:
English